Aliskiren: A Full Review of Its Pharmacology, Clinical Use and Challenges.

Snehal Ramchandra Salokhe; Rohit Vaijinath More

doi:10.71097/IJSAT.v16.i3.6791

Aliskiren: A Full Review of Its Pharmacology, Clinical Use and Challenges.

Author(s)	Ms. Snehal Ramchandra Salokhe, Mr. Rohit Vaijinath More
Country	India
Abstract	Aliskiren, the first oral active direct renin inhibitor (DRI) authorized for the treatment of hypertension, works by directly targeting renin, the enzyme that limits the rate of the renin-angiotensin-aldosterone system (RAAS). Complete RAAS suppression is achieved by this upstream inhibition, which successfully lowers angiotensin I and II levels. In terms of pharmacokinetics, aliskiren has a lengthy half-life, limited bioavailability, and little metabolism, which allows for once-daily dosage. When used alone or in conjunction with other antihypertensive medications including calcium channel blockers and thiazide diuretics, Aliskiren has shown notable clinical efficacy in reducing blood pressure. It has demonstrated potential advantages in lowering proteinuria and offering renoprotection, especially in diabetic nephropathy, in addition to hypertension. However, as the discontinued ALTITUDE trial showed, safety issues, such as the possibility of hyperkalemia and renal impairment, restrict its usage in conjunction with ACE inhibitors or ARBs, especially in high-risk patients. Although it is usually well accepted, it might cause dizziness and stomach discomfort. Newer studies investigate its wider uses, such as preventing cardiovascular disease, controlling metabolic syndrome, and reducing end-organ damage. characteristics, and changing therapeutic functions of aliskiren, highlighting its specialty in hypertension care and its prospects in broader clinical applications. However, obstacles including high cost, limited indications, and adverse event risks prevent its general adoption despite its promising potential. This review emphasizes aliskiren's significance in managing hypertension and its potential for wider clinical uses by combining its pharmacological characteristics, clinical efficacy, safety profile, and changing therapeutic roles.
Keywords	Aliskiren, Direct Renin Inhibitor, Hypertension, Renin-Angiotensin-Aldosterone System (RAAS), Pharmacology.
Field	Chemistry > Pharmacy
Published In	Volume 16, Issue 3, July-September 2025
Published On	2025-07-03
DOI	https://doi.org/10.71097/IJSAT.v16.i3.6791
Short DOI	https://doi.org/g9sx6w

View / Download PDF File

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJSAT DOI prefix is
10.71097/IJSAT

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 16 Isu 3 Cover Page Vol 16 Isu 2 Cover Page Vol 16 Isu 1

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJSAT Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us	Message on WhatsApp	+91-9687-182-185	editor@ijsat.org

International Journal on Science and Technology

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Aliskiren: A Full Review of Its Pharmacology, Clinical Use and Challenges.

Share this